{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Multiple Sclerosis",
            "NStudiesAvail": 430108,
            "NStudiesFound": 38,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 38,
            "FieldList": [
                  "PrimaryOutcomeTimeFrame",
                  "ReferenceCitation",
                  "ReferencePMID",
                  "ReferenceType",
                  "RemovedCountry",
                  "ResponsiblePartyInvestigatorAffiliation",
                  "ResponsiblePartyInvestigatorFullName",
                  "ResponsiblePartyInvestigatorTitle",
                  "ResponsiblePartyOldNameTitle",
                  "ResponsiblePartyOldOrganization",
                  "ResponsiblePartyType",
                  "ResultsFirstPostDate",
                  "ResultsFirstPostDateType",
                  "ResultsFirstPostedQCCommentsDate",
                  "ResultsFirstPostedQCCommentsDateType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "PrimaryOutcomeTimeFrame": [
                              "6 months",
                              "12 months",
                              "6 months",
                              "6 months",
                              "6 months"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01377870"
                        ]
                  },
                  {
                        "Rank": 2,
                        "PrimaryOutcomeTimeFrame": [
                              "48 weeks",
                              "48 weeks"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "Karolinska Institutet"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Ellen Iacobaeus"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Principal investigator"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT03778333"
                        ]
                  },
                  {
                        "Rank": 3,
                        "PrimaryOutcomeTimeFrame": [
                              "One year for the first phase; 4 years for the extension phase"
                        ],
                        "ReferenceCitation": [
                              "Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010 Oct;67(10):1187-94. doi: 10.1001/archneurol.2010.248."
                        ],
                        "ReferencePMID": [
                              "20937945"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "Hadassah Medical Organization"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Dimitrios Karussis"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Head of The Center for Multiple Sclerosis & Unit of Neuroimmunology"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT00781872"
                        ]
                  },
                  {
                        "Rank": 4,
                        "PrimaryOutcomeTimeFrame": [
                              "24 weeks from the first infusion",
                              "24 weeks from the first infusion"
                        ],
                        "ReferenceCitation": [
                              "Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022 Mar;59:103535. doi: 10.1016/j.msard.2022.103535. Epub 2022 Jan 19.",
                              "Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z."
                        ],
                        "ReferencePMID": [
                              "35078125",
                              "31072380"
                        ],
                        "ReferenceType": [
                              "derived",
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "University of Genova"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Antonio Uccelli"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "MD"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor-Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01854957"
                        ]
                  },
                  {
                        "Rank": 5,
                        "PrimaryOutcomeTimeFrame": [
                              "48 weeks"
                        ],
                        "ReferenceCitation": [
                              "Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z."
                        ],
                        "ReferencePMID": [
                              "31072380"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "Karolinska Institutet"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Ellen Iacobaeus"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "MD.PhD"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01730547"
                        ]
                  },
                  {
                        "Rank": 6,
                        "PrimaryOutcomeTimeFrame": [
                              "18 months"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "University of Jordan"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Fatima Jamali"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Researcher"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01895439"
                        ]
                  },
                  {
                        "Rank": 7,
                        "PrimaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "ReferenceCitation": [
                              "Llufriu S, Sep\u00falveda M, Blanco Y, Mar\u00edn P, Moreno B, Berenguer J, Gabilondo I, Mart\u00ednez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fern\u00e1ndez B, Bullich S, S\u00e1nchez-Dalmau B, Graus F, Villoslada P, Saiz A. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014."
                        ],
                        "ReferencePMID": [
                              "25436769"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "Hospital Clinic of Barcelona"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Albert Saiz"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "MD"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor-Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01228266"
                        ]
                  },
                  {
                        "Rank": 8,
                        "PrimaryOutcomeTimeFrame": [
                              "1 year after treatment"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01364246"
                        ]
                  },
                  {
                        "Rank": 9,
                        "PrimaryOutcomeTimeFrame": [
                              "24 weeks from the first infusion",
                              "24 weeks from the first infusion"
                        ],
                        "ReferenceCitation": [
                              "Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z."
                        ],
                        "ReferencePMID": [
                              "31072380"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02403947"
                        ]
                  },
                  {
                        "Rank": 10,
                        "PrimaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "ReferenceCitation": [
                              "Riordan NH, Morales I, Fern\u00e1ndez G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Paz Rodriguez J. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018 Mar 9;16(1):57. doi: 10.1186/s12967-018-1433-7. Erratum in: J Transl Med. 2021 May 10;19(1):197."
                        ],
                        "ReferencePMID": [
                              "29523171"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02034188"
                        ]
                  },
                  {
                        "Rank": 11,
                        "PrimaryOutcomeTimeFrame": [
                              "48 months following first treatment",
                              "48 months"
                        ],
                        "ReferenceCitation": [
                              "Petrou P, Kassis I, Ginzberg A, Halimi M, Yaghmour N, Abramsky O, Karussis D. Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis. Front Neurol. 2021 May 31;12:639315. doi: 10.3389/fneur.2021.639315. eCollection 2021."
                        ],
                        "ReferencePMID": [
                              "34135843"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT04823000"
                        ]
                  },
                  {
                        "Rank": 12,
                        "PrimaryOutcomeTimeFrame": [
                              "0,1,2,3,4,12 and 52 weeks post treatment"
                        ],
                        "ReferenceCitation": [
                              "Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA, Tozer DJ, Samson RS, Thomas DL, Du MQ, Luan SL, Michell AW, Altmann DR, Thompson AJ, Miller DH, Compston A, Chandran S. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. 2011 Mar 2;12:62. doi: 10.1186/1745-6215-12-62.",
                              "Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012 Feb;11(2):150-6. doi: 10.1016/S1474-4422(11)70305-2. Epub 2012 Jan 10."
                        ],
                        "ReferencePMID": [
                              "21366911",
                              "22236384"
                        ],
                        "ReferenceType": [
                              "background",
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "University of Cambridge"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Peter Connick"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Research Associate"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT00395200"
                        ]
                  },
                  {
                        "Rank": 13,
                        "PrimaryOutcomeTimeFrame": [
                              "Baseline, month 12",
                              "Baseline, month 6"
                        ],
                        "ReferenceCitation": [
                              "Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z."
                        ],
                        "ReferencePMID": [
                              "31072380"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "Germans Trias i Pujol Hospital"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Cristina Ramo"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Phase I-II clinical trial with autologous bone marrow derived mesenchymal stem cells for the therapy of mutiple sclerosis."
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02035514"
                        ]
                  },
                  {
                        "Rank": 14,
                        "PrimaryOutcomeTimeFrame": [
                              "12 months."
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01056471"
                        ]
                  },
                  {
                        "Rank": 15,
                        "PrimaryOutcomeTimeFrame": [
                              "Up to 1 year from baseline",
                              "Up to 1 year from baseline"
                        ],
                        "ReferenceCitation": [
                              "Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z."
                        ],
                        "ReferencePMID": [
                              "31072380"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01606215"
                        ]
                  },
                  {
                        "Rank": 16,
                        "PrimaryOutcomeTimeFrame": [
                              "6 months"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT04749667"
                        ]
                  },
                  {
                        "Rank": 17,
                        "PrimaryOutcomeTimeFrame": [
                              "9 months",
                              "30 months"
                        ],
                        "ReferenceCitation": [
                              "Harris VK, Faroqui R, Vyshkina T, Sadiq SA. Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med. 2012 Jul;1(7):536-47. doi: 10.5966/sctm.2012-0015. Epub 2012 Jun 28.",
                              "Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci. 2012 Feb 15;313(1-2):167-77. doi: 10.1016/j.jns.2011.08.036. Epub 2011 Oct 1.",
                              "Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002. Epub 2018 Feb 3.",
                              "Harris VK, Stark JW, Yang S, Zanker S, Tuddenham J, Sadiq SA. Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 4;8(1). pii: e928. doi: 10.1212/NXI.0000000000000928. Print 2021 Jan."
                        ],
                        "ReferencePMID": [
                              "23197858",
                              "21962795",
                              "29449193",
                              "33277427"
                        ],
                        "ReferenceType": [
                              "background",
                              "background",
                              "result",
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01933802"
                        ]
                  },
                  {
                        "Rank": 18,
                        "PrimaryOutcomeTimeFrame": [
                              "Month 36 from first treatment or placebo"
                        ],
                        "ReferenceCitation": [
                              "Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002. Epub 2018 Feb 3."
                        ],
                        "ReferencePMID": [
                              "29449193"
                        ],
                        "ReferenceType": [
                              "background"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT03355365"
                        ]
                  },
                  {
                        "Rank": 19,
                        "PrimaryOutcomeTimeFrame": [
                              "Four year follow-up"
                        ],
                        "ReferenceCitation": [
                              "Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014 Mar 25;14:58. doi: 10.1186/1471-2377-14-58. Review.",
                              "Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, Oertel FC, Scheel M, Hallimi M, Yaghmour N, Hur TB, Ginzberg A, Levy Y, Abramsky O, Karussis D. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020 Dec 1;143(12):3574-3588. doi: 10.1093/brain/awaa333.",
                              "Riordan NH, Morales I, Fern\u00e1ndez G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Paz Rodriguez J. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018 Mar 9;16(1):57. doi: 10.1186/s12967-018-1433-7. Erratum in: J Transl Med. 2021 May 10;19(1):197.",
                              "Li JF, Zhang DJ, Geng T, Chen L, Huang H, Yin HL, Zhang YZ, Lou JY, Cao B, Wang YL. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. 2014;23 Suppl 1:S113-22. doi: 10.3727/096368914X685005. Epub 2014 Nov 5."
                        ],
                        "ReferencePMID": [
                              "24666846",
                              "33253391",
                              "29523171",
                              "25385295"
                        ],
                        "ReferenceType": [
                              "background",
                              "background",
                              "background",
                              "background"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT05003388"
                        ]
                  },
                  {
                        "Rank": 20,
                        "PrimaryOutcomeTimeFrame": [
                              "from visit 2 to 12-month follow-up period",
                              "from visit 2 to 12-month follow-up period"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT05532943"
                        ]
                  },
                  {
                        "Rank": 21,
                        "PrimaryOutcomeTimeFrame": [
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 Months"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02326935"
                        ]
                  },
                  {
                        "Rank": 22,
                        "PrimaryOutcomeTimeFrame": [
                              "3-6 months"
                        ],
                        "ReferenceCitation": [
                              "Alghwiri AA, Jamali F, Aldughmi M, Khalil H, Al-Sharman A, Alhattab D, Al-Radaideh A, Awidi A. The effect of stem cell therapy and comprehensive physical therapy in motor and non-motor symptoms in patients with multiple sclerosis: A comparative study. Medicine (Baltimore). 2020 Aug 21;99(34):e21646. doi: 10.1097/MD.0000000000021646."
                        ],
                        "ReferencePMID": [
                              "32846775"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "University of Jordan"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Fatima Jamali"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Head of Neuroscience Research"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT03326505"
                        ]
                  },
                  {
                        "Rank": 23,
                        "PrimaryOutcomeTimeFrame": [
                              "1 month"
                        ],
                        "ReferenceCitation": [
                              "Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6."
                        ],
                        "ReferencePMID": [
                              "28381130"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT00813969"
                        ]
                  },
                  {
                        "Rank": 24,
                        "PrimaryOutcomeTimeFrame": [
                              "24 weeks from first infusion",
                              "24 weeks from first infusion"
                        ],
                        "ReferenceCitation": [
                              "Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022 Mar;59:103535. doi: 10.1016/j.msard.2022.103535. Epub 2022 Jan 19.",
                              "Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z."
                        ],
                        "ReferencePMID": [
                              "35078125",
                              "31072380"
                        ],
                        "ReferenceType": [
                              "derived",
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02239393"
                        ]
                  },
                  {
                        "Rank": 25,
                        "PrimaryOutcomeTimeFrame": [],
                        "ReferenceCitation": [
                              "Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002. Epub 2018 Feb 3."
                        ],
                        "ReferencePMID": [
                              "29449193"
                        ],
                        "ReferenceType": [
                              "background"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT03822858"
                        ]
                  },
                  {
                        "Rank": 26,
                        "PrimaryOutcomeTimeFrame": [
                              "Up to 12 months"
                        ],
                        "ReferenceCitation": [
                              "Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006 Feb;5(2):158-70. Review.",
                              "Coles A. The curious incident of disability in multiple sclerosis trials. Lancet Neurol. 2006 Nov;5(11):899-900.",
                              "Bjartmar C, Kidd G, M\u00f6rk S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000 Dec;48(6):893-901.",
                              "Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):43-9. doi: 10.1002/ana.24018. Epub 2014 Jan 2.",
                              "Till C, Ghassemi R, Aubert-Broche B, Kerbrat A, Collins DL, Narayanan S, Arnold DL, Desrocher M, Sled JG, Banwell BL. MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. Neuropsychology. 2011 May;25(3):319-32. doi: 10.1037/a0022051.",
                              "Yaldizli \u00d6, Penner IK, Frontzek K, Naegelin Y, Amann M, Papadopoulou A, Sprenger T, Kuhle J, Calabrese P, Rad\u00fc EW, Kappos L, Gass A. The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler. 2014 Mar;20(3):356-64. doi: 10.1177/1352458513496880. Epub 2013 Aug 19.",
                              "Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci. 2009 Jul 15;282(1-2):106-11. doi: 10.1016/j.jns.2008.11.018. Epub 2008 Dec 19.",
                              "Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 May;5(5):256-66. doi: 10.1038/nrneurol.2009.41. Review.",
                              "Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, De Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BM, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H; MAGNIMS Study Group. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1082-91. doi: 10.1136/jnnp-2012-304094. Epub 2013 Mar 23.",
                              "Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, V\u00e9csei L, Milanov I. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006 Jul;13(7):700-22. Review.",
                              "Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringd\u00e9n O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008 May 10;371(9624):1579-86. doi: 10.1016/S0140-6736(08)60690-X.",
                              "Le Blanc K, Rasmusson I, Sundberg B, G\u00f6therstr\u00f6m C, Hassan M, Uzunel M, Ringd\u00e9n O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41.",
                              "Kurtzke JF. Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology. 2008;31(1):1-9. doi: 10.1159/000136645. Epub 2008 Jun 6. Review.",
                              "Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997 Sep;42(3):379-82.",
                              "Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 May;122 ( Pt 5):871-82.",
                              "Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? Mult Scler. 2009 Sep;15(9):1043-7. doi: 10.1177/1352458509106610. Epub 2009 Jul 1.",
                              "Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999 Mar 20;353(9157):964-9.",
                              "Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002 Jan 17;346(3):158-64.",
                              "O'Riordan JI, Gawne Cain M, Coles A, Wang L, Compston DA, Tofts P, Miller DH. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler. 1998 Oct;4(5):408-12.",
                              "Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, Kornberg A, Krupp LB, Pohl D, Rostasy K, Tenembaum S, Waubant E, Wassmer E. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 2013 Mar 19;80(12):1161-8. doi: 10.1212/WNL.0b013e318288694e.",
                              "Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009 Mar;65(3):268-75. doi: 10.1002/ana.21606.",
                              "Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler. 2011 May;17(5):541-9. doi: 10.1177/1352458510391837. Epub 2010 Dec 9.",
                              "Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L, Filippi M; European Study Group on Interferon Beta-1b in Secondary Progressive MS. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. Neurology. 2003 May 13;60(9):1462-6.",
                              "Pascual AM, Mart\u00ednez-Bisbal MC, Bosc\u00e1 I, Valero C, Coret F, Mart\u00ednez-Granados B, Marti-Bonmati L, Mir A, Celda B, Casanova B. Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology. 2007 Jul 3;69(1):63-7.",
                              "Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, McIntosh KR. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47-57.",
                              "Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringd\u00e9n O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003 Jan;57(1):11-20.",
                              "Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y. A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther. 2014 Apr 23;5(2):57. doi: 10.1186/scrt446.",
                              "Watson N, Divers R, Kedar R, Mehindru A, Mehindru A, Borlongan MC, Borlongan CV. Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. Cytotherapy. 2015 Jan;17(1):18-24. doi: 10.1016/j.jcyt.2014.08.009. Epub 2014 Oct 18. Review.",
                              "Mikaeili Agah E, Parivar K, Joghataei MT. Therapeutic effect of transplanted human Wharton's jelly stem cell-derived oligodendrocyte progenitor cells (hWJ-MSC-derived OPCs) in an animal model of multiple sclerosis. Mol Neurobiol. 2014 Apr;49(2):625-32. doi: 10.1007/s12035-013-8543-2. Epub 2013 Aug 28."
                        ],
                        "ReferencePMID": [
                              "16426992",
                              "17052654",
                              "11117546",
                              "24006277",
                              "21534686",
                              "23959709",
                              "19100997",
                              "19488083",
                              "23524331",
                              "16834700",
                              "18468541",
                              "15121408",
                              "18535394",
                              "9307263",
                              "10355672",
                              "19570818",
                              "10459905",
                              "11796849",
                              "9839300",
                              "23509048",
                              "19334061",
                              "21148262",
                              "12743232",
                              "17606882",
                              "15864738",
                              "12542793",
                              "24759263",
                              "25442786",
                              "23982748"
                        ],
                        "ReferenceType": [
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "result",
                              "result",
                              "result",
                              "result",
                              "result"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02587715"
                        ]
                  },
                  {
                        "Rank": 27,
                        "PrimaryOutcomeTimeFrame": [
                              "Up to 12 months"
                        ],
                        "ReferenceCitation": [
                              "Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006 Feb;5(2):158-70. Review.",
                              "Coles A. The curious incident of disability in multiple sclerosis trials. Lancet Neurol. 2006 Nov;5(11):899-900.",
                              "Bjartmar C, Kidd G, M\u00f6rk S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000 Dec;48(6):893-901.",
                              "Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):43-9. doi: 10.1002/ana.24018. Epub 2014 Jan 2.",
                              "Till C, Ghassemi R, Aubert-Broche B, Kerbrat A, Collins DL, Narayanan S, Arnold DL, Desrocher M, Sled JG, Banwell BL. MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. Neuropsychology. 2011 May;25(3):319-32. doi: 10.1037/a0022051.",
                              "Yaldizli \u00d6, Penner IK, Frontzek K, Naegelin Y, Amann M, Papadopoulou A, Sprenger T, Kuhle J, Calabrese P, Rad\u00fc EW, Kappos L, Gass A. The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler. 2014 Mar;20(3):356-64. doi: 10.1177/1352458513496880. Epub 2013 Aug 19.",
                              "Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci. 2009 Jul 15;282(1-2):106-11. doi: 10.1016/j.jns.2008.11.018. Epub 2008 Dec 19.",
                              "Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 May;5(5):256-66. doi: 10.1038/nrneurol.2009.41. Review.",
                              "Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, De Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BM, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H; MAGNIMS Study Group. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1082-91. doi: 10.1136/jnnp-2012-304094. Epub 2013 Mar 23.",
                              "Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, V\u00e9csei L, Milanov I. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006 Jul;13(7):700-22. Review.",
                              "Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringd\u00e9n O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008 May 10;371(9624):1579-86. doi: 10.1016/S0140-6736(08)60690-X.",
                              "Le Blanc K, Rasmusson I, Sundberg B, G\u00f6therstr\u00f6m C, Hassan M, Uzunel M, Ringd\u00e9n O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41.",
                              "Kurtzke JF. Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology. 2008;31(1):1-9. doi: 10.1159/000136645. Epub 2008 Jun 6. Review.",
                              "Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997 Sep;42(3):379-82.",
                              "Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 May;122 ( Pt 5):871-82.",
                              "Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? Mult Scler. 2009 Sep;15(9):1043-7. doi: 10.1177/1352458509106610. Epub 2009 Jul 1.",
                              "Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999 Mar 20;353(9157):964-9.",
                              "Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002 Jan 17;346(3):158-64.",
                              "O'Riordan JI, Gawne Cain M, Coles A, Wang L, Compston DA, Tofts P, Miller DH. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler. 1998 Oct;4(5):408-12.",
                              "Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, Kornberg A, Krupp LB, Pohl D, Rostasy K, Tenembaum S, Waubant E, Wassmer E. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 2013 Mar 19;80(12):1161-8. doi: 10.1212/WNL.0b013e318288694e.",
                              "Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009 Mar;65(3):268-75. doi: 10.1002/ana.21606.",
                              "Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler. 2011 May;17(5):541-9. doi: 10.1177/1352458510391837. Epub 2010 Dec 9.",
                              "Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L, Filippi M; European Study Group on Interferon Beta-1b in Secondary Progressive MS. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. Neurology. 2003 May 13;60(9):1462-6.",
                              "Pascual AM, Mart\u00ednez-Bisbal MC, Bosc\u00e1 I, Valero C, Coret F, Mart\u00ednez-Granados B, Marti-Bonmati L, Mir A, Celda B, Casanova B. Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology. 2007 Jul 3;69(1):63-7.",
                              "Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, McIntosh KR. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47-57.",
                              "Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringd\u00e9n O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003 Jan;57(1):11-20.",
                              "Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y. A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther. 2014 Apr 23;5(2):57. doi: 10.1186/scrt446.",
                              "Watson N, Divers R, Kedar R, Mehindru A, Mehindru A, Borlongan MC, Borlongan CV. Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. Cytotherapy. 2015 Jan;17(1):18-24. doi: 10.1016/j.jcyt.2014.08.009. Epub 2014 Oct 18. Review.",
                              "Mikaeili Agah E, Parivar K, Joghataei MT. Therapeutic effect of transplanted human Wharton's jelly stem cell-derived oligodendrocyte progenitor cells (hWJ-MSC-derived OPCs) in an animal model of multiple sclerosis. Mol Neurobiol. 2014 Apr;49(2):625-32. doi: 10.1007/s12035-013-8543-2. Epub 2013 Aug 28."
                        ],
                        "ReferencePMID": [
                              "16426992",
                              "17052654",
                              "11117546",
                              "24006277",
                              "21534686",
                              "23959709",
                              "19100997",
                              "19488083",
                              "23524331",
                              "16834700",
                              "18468541",
                              "15121408",
                              "18535394",
                              "9307263",
                              "10355672",
                              "19570818",
                              "10459905",
                              "11796849",
                              "9839300",
                              "23509048",
                              "19334061",
                              "21148262",
                              "12743232",
                              "17606882",
                              "15864738",
                              "12542793",
                              "24759263",
                              "25442786",
                              "23982748"
                        ],
                        "ReferenceType": [
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "background",
                              "result",
                              "result",
                              "result",
                              "result",
                              "result"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02418325"
                        ]
                  },
                  {
                        "Rank": 28,
                        "PrimaryOutcomeTimeFrame": [
                              "6 months for each treatment cycle; the two cycles (each of 6 months duration) will be combined together and provide a single measurement for each group",
                              "6 months for each treatment cycle; the two cycles (each of 6 months duration) will be combined together and provide a single measurement for each group"
                        ],
                        "ReferenceCitation": [
                              "Petrou P, Kassis I, Ginzberg A, Hallimi M, Karussis D. Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis. Stem Cells Transl Med. 2022 Mar 3;11(1):55-58. doi: 10.1093/stcltm/szab017.",
                              "Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, Oertel FC, Scheel M, Hallimi M, Yaghmour N, Hur TB, Ginzberg A, Levy Y, Abramsky O, Karussis D. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020 Dec 1;143(12):3574-3588. doi: 10.1093/brain/awaa333."
                        ],
                        "ReferencePMID": [
                              "35641166",
                              "33253391"
                        ],
                        "ReferenceType": [
                              "derived",
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "Hadassah Medical Organization"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Dimitrios Karussis"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Head of The Center for Multiple Sclerosis & Unit of Neuroimmunology"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor-Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02166021"
                        ]
                  },
                  {
                        "Rank": 29,
                        "PrimaryOutcomeTimeFrame": [
                              "Baseline to Week 52"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT05116540"
                        ]
                  },
                  {
                        "Rank": 30,
                        "PrimaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "ReferenceCitation": [
                              "Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z."
                        ],
                        "ReferencePMID": [
                              "31072380"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT01745783"
                        ]
                  },
                  {
                        "Rank": 31,
                        "PrimaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02495766"
                        ]
                  },
                  {
                        "Rank": 32,
                        "PrimaryOutcomeTimeFrame": [
                              "Day 1 to Month 60",
                              "Day 1 to Month 60"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT04956744"
                        ]
                  },
                  {
                        "Rank": 33,
                        "PrimaryOutcomeTimeFrame": [
                              "Up to 28 weeks post-treatment"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT03799718"
                        ]
                  },
                  {
                        "Rank": 34,
                        "PrimaryOutcomeTimeFrame": [
                              "6 months",
                              "12 months"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT03069170"
                        ]
                  },
                  {
                        "Rank": 35,
                        "PrimaryOutcomeTimeFrame": [
                              "change from baseline to one year"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "Tianjin Medical University General Hospital"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Fu-Dong Shi"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Head of Neurology Department"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT02249676"
                        ]
                  },
                  {
                        "Rank": 36,
                        "PrimaryOutcomeTimeFrame": [
                              "Up to 18 months: starting from inclusion until 3 months after the last MSC-injection",
                              "Up to 18 months: starting from inclusion until 3 months after the last MSC-injection."
                        ],
                        "ReferenceCitation": [
                              "Petrou P, Kassis I, Yaghmour NE, Ginzberg A, Karussis D. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. Front Biosci (Landmark Ed). 2021 Oct 30;26(10):693-706. doi: 10.52586/4980."
                        ],
                        "ReferencePMID": [
                              "34719198"
                        ],
                        "ReferenceType": [
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Sponsor"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT04821479"
                        ]
                  },
                  {
                        "Rank": 37,
                        "PrimaryOutcomeTimeFrame": [
                              "up to 12 months post injection"
                        ],
                        "ReferenceCitation": [],
                        "ReferencePMID": [],
                        "ReferenceType": [],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [
                              "Mayo Clinic"
                        ],
                        "ResponsiblePartyInvestigatorFullName": [
                              "Mohamad Bydon"
                        ],
                        "ResponsiblePartyInvestigatorTitle": [
                              "Principal Investigator"
                        ],
                        "ResponsiblePartyOldNameTitle": [],
                        "ResponsiblePartyOldOrganization": [],
                        "ResponsiblePartyType": [
                              "Principal Investigator"
                        ],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT04520373"
                        ]
                  },
                  {
                        "Rank": 38,
                        "PrimaryOutcomeTimeFrame": [
                              "monthly"
                        ],
                        "ReferenceCitation": [
                              "Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009 Jun;27(6):1421-32. doi: 10.1002/stem.68.",
                              "Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z, Sun L. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler. 2009 May;15(5):644-6. doi: 10.1177/1352458509104590.",
                              "Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol. 2008 Dec;5(6):417-24. doi: 10.1038/cmi.2008.52.",
                              "Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus. 2007;16(2):121-8.",
                              "Zhang H, Liang J, Tang X, Wang D, Feng X, Wang F, Hua B, Wang H, Sun L. Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther. 2017 Jul 19;19(1):165. doi: 10.1186/s13075-017-1373-2.",
                              "Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012 May 4;10(5):544-55. doi: 10.1016/j.stem.2012.03.007. Epub 2012 Apr 26."
                        ],
                        "ReferencePMID": [
                              "19489103",
                              "19389752",
                              "19118507",
                              "17402368",
                              "28724445",
                              "22542159"
                        ],
                        "ReferenceType": [
                              "background",
                              "background",
                              "background",
                              "background",
                              "derived",
                              "derived"
                        ],
                        "RemovedCountry": [],
                        "ResponsiblePartyInvestigatorAffiliation": [],
                        "ResponsiblePartyInvestigatorFullName": [],
                        "ResponsiblePartyInvestigatorTitle": [],
                        "ResponsiblePartyOldNameTitle": [
                              "the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"
                        ],
                        "ResponsiblePartyOldOrganization": [
                              "the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"
                        ],
                        "ResponsiblePartyType": [],
                        "ResultsFirstPostDate": [],
                        "ResultsFirstPostDateType": [],
                        "ResultsFirstPostedQCCommentsDate": [],
                        "ResultsFirstPostedQCCommentsDateType": [],
                        "NCTId": [
                              "NCT00962923"
                        ]
                  }
            ]
      }
}